Refine by
Cancerous Target Articles & Analysis
246 news found
Research on molecular targeted therapy for tumors is increasing, and new targeted therapeutic agents are emerging. ...
Expanding the Horizon with Advanced Anti-Tumor APIs Protheragen-ING’s new anti-tumor APIs are a quantum leap forward for cancer therapy. Such APIs come in a wide range of types: chemotherapeutic, targeted, immunotherapeutic, hormone therapeutic. The APIs in chemotherapy work by interfering with the cell division mechanism to suppress cancer ...
One of the standout technologies on display was Creative Biolabs' phage display service, which enables the selection of antibodies with high specificity and affinity against a wide range of targets. During the event, the team demonstrated their pipeline from phage construction to screening and their masterpiece in discovering PTM specific antibodies, anti-idiotype antibodies, ...
It is a practical and effective tool for high-throughput molecular analysis of tissues, helping to identify new diagnostic and prognostic markers and targets for human cancers, with a wide range of potential applications in basic research, tumor prognosis and drug discovery. ...
It is well established that oncogenic alterations, such as mutations and fusions, can lead to malignant cellular growth that results in cancer. While approved targeted agents are available to treat several types of oncogenic mutations, patients whose cancers harbor oncogene amplification typically do not derive the same benefit. Oncogenes can be ...
DOE and its National Laboratories have invested in AI since the 1960s, developing cutting-edge tools with applications that range from managing an increasingly complex energy grid to accelerating discovery in targeted treatments for cancer. DOE's data science and high-performance computing capabilities for both open science and classified needs and longstanding ...
This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge protein drug design. ...
Focal treatment is where doctors target only the cancer that requires intervention and can be the bridge between active surveillance and radical treatment. This is like other cancers such as kidney and breast cancer, where treating the cancer while preserving the healthy tissue is the first consideration for ...
Creative Diagnostics now offers new reagent solutions to assist researchers in herpesvirus research, including antibodies that target specific steps in the herpesvirus entry process. Scientists can utilize these antibodies to study how herpesviruses enter cells, facilitating the development of new antiviral drugs. ...
Antitumor therapy now focuses on targeting enzymes that are abnormally expressed in cancer cells. Three irreversible and numerous reversible enzymatic reactions can occur along the glycolytic pathway. The metabolic reprogramming of cancer involves modifications in the glycolytic pathway's enzymatic response in cancer cells. ...
Bayer is advancing its oncology R&D efforts in three scientific areas that have the potential to address unmet needs in cancer patients: next-generation Immuno-Oncology, Targeted Radionuclide Therapies and Precision Molecular Oncology. ...
ByBayer AG
Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, headquartered in New York and focused on bringing transformational oncology treatments for cancer patients, will commercialize ORSERDU in the U.S. “The FDA approval of ORSERDU marks the first ever therapy for ER+, HER2- advanced or metastatic breast cancer ...
Tulmimetostat is an oral, investigational next-generation selective dual inhibitor of EZH2 and EZH1 designed to improve on first generation EZH2 inhibitors via increased potency, longer residence time on target and a longer half-life. The data were presented during poster sessions at the 34th Symposium on Molecular Targets and Cancer Therapeutics ...
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc. ...
This improved outlook comes amid the company’s potential blockbuster drugs tracking ahead of schedule and targeted investments in Research and Development (R&D) replenishing its pharmaceutical development pipeline. ...
ByBayer AG
It provides protection for both autologous (patient-derived) and allogeneic (off-the-shelf) immune cell products that carry the TAG-72 CAR. TAG-72 a well-validated target, highly expressed on a range of adenocarcinomas including ovarian and gastric cancers. Issuance of the patent is an important milestone in underpinning the development of new treatments for ...
” iBio’s RubrYc Discovery Engine is designed to tackle complex and challenging drug targets with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. It uses a combination of a proprietary epitope steering technology, a specialized antibody library, and AI-powered antibody optimization to quickly identify ...
Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic ...
ByxCures
(Nasdaq: LIXT), is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Major drivers of cancer are defects in the switches that turn the biochemical pathways in cells on or off. ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers ...